On October 2, 2025 OncoC4, Inc. a clinical-stage biotechnology company, reported the recent closing of a Series B financing round of nearly $50 million (Press release, OncoC4, OCT 2, 2025, View Source [SID1234656411]). The round was led by GBA Fund, and supported by additional capital from the Company’s co-founders and existing investors, including HM Capital, 3E Bioventures Capital and Kaitai Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OncoC4 was founded in 2020 by two renowned immunologists and serial entrepreneurs, Dr. Yang Liu and Dr. Pan Zheng. By leveraging deep expertise in immuno-oncology and translational medicine, the Company has built a broad pipeline of innovative therapies with first-in-class or best-in-class potential. The proceeds from the Series B financing will primarily be used to support the advancement of the clinical development of the Company’s pipeline programs.

"Our Series B financing round progressed rapidly, and we deeply appreciate our investors’ recognition of our Company and continual support," said Dr. Yang Liu, Co-Founder, Chairman of the Board, CEO and CSO of OncoC4. "We are committed to rigorously advancing the global development of our core pipeline, while strategically expanding business development activities, with the ultimate goal of delivering more disruptive therapies to patients worldwide."